Evidence map›Paper›PMID 40877472›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2025

Achievement rate of blood pressure control <130/80 mmHg as the core metric of implementation hypertension, based on the new JSH2025 and AHA/ACC2025 guidelines.

Kazuomi Kario

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Beyond office blood pressure: J-SAMIT and the emerging era of implementation hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  4. What is "Implementation Hypertension"? Uniting individuals, healthcare, and society around blood pressure.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kazuomi KarioDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan. kkario@jichi.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent updates to international hypertension guidelines have converged toward a therapeutic target of <130/80 mmHg, as reflected in the JSH2025, AHA/ACC2025, and ESC2024 recommendations. Strong evidence from major outcome trials such as SPRINT, STEP, BPROAD, and ESPRIT has consistently demonstrated the benefit of intensive blood pressure (BP) control, particularly systolic BP < 130 mmHg, across a wide spectrum of hypertensive populations, including the elderly and those with diabetes, CKD, or cardiovascular comorbidities. The JSH2025 guidelines further emphasize home BP management, setting a lower target of <125/75 mmHg, supported by prospective nationwide studies such as J-HOP and HONEST. However, despite these advances in evidence and recommendations, real-world BP control rates remain unsatisfactory, underscoring the critical need for effective implementation strategies. To address this gap, we propose the "achievement rate of BP control <130/80 mmHg" as a unified, core implementation metric for hypertension management. This target is consistent with both JSH2025 and AHA/ACC2025 guidelines, as well as with Japan's Asakatsu campaign. We further recommend a dual-layered evaluation framework: a macro-approach (spatial, population-level) using office BP or health-check BP to assess outcomes in the general hypertensive population, and a micro-approach (temporal, individual-level) using home BP to monitor the quality of daily management and treatment adherence. Adopting this integrated framework will enable the simultaneous assessment of both public health impact and individualized care quality, providing a practical and evidence-based index for bridging guidelines with daily clinical practice. Ultimately, widespread application of this unified implementation metric has the potential to accelerate progress toward improved global cardiovascular outcomes. Core metric 130/80 mmHg of implementation hypertension. BP, blood pressure.

Indexed as

Antihypertensive AgentsBlood PressureHypertensionPractice Guidelines as TopicAmerican Heart AssociationHumansAntihypertensive AgentsAHA/ACC2025 guidelinesblood pressure goalhome blood pressureimplementation hypertensinJSH2025 guidelines

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.